IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.
Unresectable Locally Advanced or Metastatic Solid Tumors
DRUG: IBI3014|DRUG: IBI3014|DRUG: IBI3014|DRUG: IBI3014|DRUG: IBI3014|DRUG: IBI3014
The Safety profile of patients in Phase 1 dose escalation part, Occurrence and severity of adverse events (AEs), change of labolatory items, physical examination and vital signs, with severity determined by NCI CTCAE v5.0 criteria, 2 years after LPI|Dose limiting toxicity (DLT) of IBI3014 in Phase 1 dose escalation, The occurance of Dose limiting toxicity (DLT) per protocol to establish MTD or RP2D, 21 days after LPI|ORR per RECIST v1.1 in Phase 1 dose expansion and Phase 2 dose optimization, The investigator assessed ORR per RECIST v1.1, 2 years after LPI|The Safety profile of patients in Phase 1 dose expansion and Phase 2 dose optimization, Occurrence and severity of adverse events (AEs), change of labolatory items, physical examination and vital signs, with severity determined by NCI CTCAE v5.0 criteria, 2 years after LPI
Efficacy of IBI3014, DOR, DoR, TTR, PFS as evaluated by investigator per RECIST v1.1 criteria and OS, 2 years after LPI|PK profile of IBI3014, area under the curve (AUC), Cmax, Tmax, Clearance and t1/2 and others, 2 years after LPI|Incidence and characterization of anti-IBI3014 antibodies., Rate of ADA and Nab, 2 years after LPI
This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.